Skip to main content

Roche, Exiqon Reach Co-Marketing Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche Applied Science and Exiqon today announced a joint marketing agreement covering Roche's RealTime ready assays and Exiqon's miRCURY LNA Universal RT microRNA pPCR system.

Financial terms were not disclosed.

Roche's RealTime assays are based on Exiqon's Universal ProbeLibrary technology and offer "maximized testing efficiency," Exiqon said in a statement. In 2008, the two firms inked a deal under which Roche was given co-exclusive rights to use Exiqon's Universal ProbeLibrary of LNA oligonucleotides to develop and manufacture its RealTime ready qPCR assays.

Exiqon said today that its LNA-enhanced PCR primers have "exceptional" sensitivity and specificity, "enabling accurate quantification of very low amounts of microRNA obtained from difficult samples," including frozen formalin paraffin-embedded tissue, serum, plasma, and laser capture microscopy.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.